SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stripe, Advent to Buy PayPal in a $53B Deal? ETFs in Focus

Stripe and Advent have made a $53B bid for PayPal, lifting PYPL shares and putting fintech ETFs like PYPU, FINX and IPAY in the spotlight.

AFRM Stock Headed For Third Week Of Gains - Morgan Stanley Names Affirm 'Top Pick' 

Equity

The firm maintained its ‘Overweight’ rating and assigned a $76 price target, implying a 26% upside potential.


Why Did DLO Stock Jump After-Hours Today?

DLO’s Total Payment Volume reached a record $13.1 billion in the fourth quarter, up 70% year-over-year. 


PayPal Eyes 70-Country PYUSD Expansion With Rewards For Its Stablecoin, Despite CLARITY Act Limbo

Cryptocurrency

May Zabaneh, PayPal’s head of crypto and senior vice president, told Fortune that the company is planning to to expand its PYUSD stablecoin to 70 countries by the end of the month.

Affirm Gets A Morgan Stanley Upgrade Ahead Of Earnings – Firm Sees AFRM Stock’s Weakness As A ‘Compelling’ Opportunity 

The firm’s review suggests the challenges impacting Affirm are likely temporary and should ease over time. 

ETFs Likely to Benefit from Thanksgiving Weekend Sales

Thanksgiving shopping is set to boost retail and tech ETFs. XRT, IBUY, ONLN, IPAY, BPAY and PSCD could be the biggest winners of the holiday spending boom.

Feast on 4 Thanksgiving-Themed ETFs Now

Feast on seasonal trends with Thanksgiving-themed ETFs. From retail (RTH) to travel tech (AWAY), restaurants (EATZ) and fintech (BPAY), these picks may shine.

AI Meets Finance: ETFs in Spotlight as PayPal-OpenAI Seal Deal 

PayPal's new role as ChatGPT's default wallet cements its AI-commerce leadership and draws ETF investors seeking fintech growth exposure.  

PayPal Falls Despite Q2 Earnings Beating Estimates: ETFs in Focus

PayPal topped Q2 earnings and revenue estimates but slid 8% as slowing transaction margins weighed on investor sentiment. ETFs like IPAY and FINX should be monitored closely. 

Block Surges on S&P 500 Inclusion: ETFs in Focus

Block (XYZ) surged 8.5% in extended trading on July 18, 2025, following news of its inclusion in the S&P 500, replacing Hess and drawing investor attention to ETFs like SPYA and DAPP, which are expected to benefit.

Amplify ETF Trust - Amplify Digital Payments ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Morgan Stanley sees potential upward revisions across key metrics, including gross merchandise volume, margins, and earnings.</li><li>The firm said concerns around private credit exposure are overstated.</li><li>The Investor Forum in May could act as a catalyst for higher guidance and stock momentum.</li></ul>Affirm Holdings Inc. (AFRM) is looking for a third straight week of gains, supported by a bullish call from Morgan Stanley, which identified the buy-now-pay-later provider as its top investment idea amid improving growth expectations and upcoming catalysts.The firm reiterated its ‘Overweight’ rating on the stock and set a $76 price target, implying a 26% upside potential from the stock’s closing price on Thursday.<h2 class="st-heading-2">Estimate Revisions In Focus</h2>Analyst James Faucette expects Affirm’s upcoming Investor Forum in May to serve as a key inflection point, according to TheFly.&nbsp;Faucette indicated that Affirm could see upgrades to its projections for gross merchandise volume, profitability, and earnings per share. The company may provide updated financial targets in the event, reinforcing its medium-term growth trajectory,&nbsp;he stated.&nbsp;<a href="https://stocktwits.com/symbol/AFRM">Affirm stock</a> traded over 6% higher on Friday afternoon. On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_17_132839_png_6f2f7b3fc9.webp" alt="AFRM’s Sentiment Meter and Message Volume as of 13:00 p.m. ET on Apr.17, 2026 | Source: Stocktwits" width="931" height="102"><figcaption>AFRM’s Sentiment Meter and Message Volume as of 13:00 p.m. ET on Apr.17, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Credit Concerns Seen As Overdone</h2>Investor anxiety around private credit exposure has weighed on sentiment in recent months, but Morgan Stanley believes those fears may be exaggerated.&nbsp;According to a CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/04/17/this-payments-stock-is-poised-to-rally-on-strong-catalysts-morgan-stanley-says.html">report</a>, the firm noted that asset-backed securities spreads have remained stable, indicating continued access to funding and healthy demand from capital markets.“AFRM is our Top Pick on upward estimate revision potential, overdone private credit fears, and a strong catalyst path,” said Faucette.The company is also scheduled to report its third-quarter earnings on May 7. Analysts expect revenue of $995.7 million and earnings per share (EPS) of $0.68, according to Fiscal AI data.&nbsp;AFRM stock has declined by over 13% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intc-stock-hits-25-year-high-retail-believes-next-week-will-be-most-important-for-intel/cZJUun1RIU5">INTC Stock Hits 25-Year High: Retail Believes Next Week Will Be 'Most Important’ For Intel</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Affirm Holdings Inc. logo is seen on a smartphone in a hand. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

The firm maintained its ‘Overweight’ rating and assigned a $76 price target, implying a 26% upside potential.

Affirm Holdings Inc

Global X Funds - Global X Funds Global X FinTech ETF

Amplify Digital Payments ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

IPAY Amplify Digital Payments ETF

Fundamentals

Latest IPAY News